Exonate Sees Alternative mRNA Splicing Inhibitors As New Eye Disease Therapies
Executive Summary
Emerging Company Profile: Inhibitors of VEGF-A alternative mRNA splicing could deliver a step-change in the treatment of retinal eye diseases, hopes UK start-up Exonate.